Best Ophthalmologists for Age-Related Macular Degeneration (AMD) Management in India

Age-related macular degeneration (AMD) is a degenerative condition of the macula — the central part of the retina — that gradually damages central vision, typically in people aged 50 and older. It occurs in two principal forms: dry AMD, which progresses slowly through the accumulation of drusen (protein and lipid deposits) and retinal cell atrophy, and wet AMD, which involves abnormal blood vessel growth beneath the retina and can cause more rapid vision loss.

Early AMD may produce no noticeable symptoms, while intermediate or advanced stages can cause blurred or distorted central vision, difficulty reading or seeing fine detail, a need for brighter lighting, and the perception of straight lines appearing wavy or bent — a symptom assessed using a grid tool called an Amsler chart. In advanced wet AMD, a dark or blank spot (scotoma) may develop in the centre of the visual field, and colours may appear less vivid. It is important to note that these symptoms can overlap with other retinal and ocular conditions, and their presence alone does not confirm a diagnosis of AMD.

Diagnosis is typically established through a comprehensive dilated eye examination combined with specialised imaging, most importantly optical coherence tomography (OCT), which provides detailed cross-sectional images of the retina and macula and allows clinicians to detect and grade structural changes including drusen size and distribution, geographic atrophy, and the presence of subretinal fluid or choroidal neovascularisation. Fundus photography and, where wet AMD is suspected, fluorescein or OCT angiography may also be used to map abnormal blood vessel activity. AMD severity is commonly categorised using established grading systems such as the Age-Related Eye Disease Study (AREDS) scale, which helps stratify risk of progression and inform treatment planning.

The appropriate management of AMD depends on its type, stage, and rate of progression as determined by a qualified ophthalmologist following full clinical assessment. Dry AMD, particularly in early and intermediate stages, is often managed through monitoring, lifestyle modification, and nutritional supplementation, while advanced dry AMD with geographic atrophy has limited but emerging treatment options. Wet AMD — and some cases of advanced dry AMD — is primarily treated with intravitreal anti-VEGF injections, a procedural intervention administered directly into the eye to suppress abnormal blood vessel growth and limit further vision loss; the number and frequency of injections required varies by individual response and is decided by the treating clinician.

Non-procedural management plays a meaningful role in AMD care, particularly for early and intermediate dry AMD, and typically includes regular monitoring with OCT and dilated eye exams, high-dose antioxidant and zinc supplementation based on the AREDS2 formula (for eligible patients at intermediate or advanced risk), smoking cessation, management of cardiovascular risk factors, and the use of protective eyewear to reduce UV exposure. For wet AMD or advanced dry AMD, non-surgical measures alone are generally insufficient to prevent significant vision loss, and procedural treatment such as anti-VEGF injections is usually recommended — though the timing and approach depend on individual clinical assessment.

Age-related Macular Degeneration (AMD) Management may be considered only when it is appropriate for the confirmed diagnosis and the expected benefit outweighs the individual risks. The decision may depend on symptom severity, investigation results, previous treatment, overall health and the patient's goals. A specialist should discuss alternatives and recovery before any procedure is planned.

AMD is evaluated and managed by a retinal specialist — an ophthalmologist with subspecialty training in diseases and surgery of the retina and vitreous — who will conduct retinal imaging and interpret grading to guide treatment. In some settings, a general ophthalmologist may identify and initially assess AMD before referring to a vitreoretinal subspecialist for ongoing management of intermediate or advanced disease.

When selecting a specialist for AMD care, it is worth considering the clinician's specific experience in retinal disease and AMD management, their access to up-to-date retinal imaging technology such as OCT and angiography, and whether the facility supports a structured follow-up programme, since AMD — particularly wet AMD treated with anti-VEGF injections — typically requires ongoing monitoring and repeated clinic visits to assess treatment response and adjust the care plan.

Share a concise medical summary, symptom timeline, previous diagnoses, investigation and imaging reports, procedure or biopsy reports where relevant, current medicines, allergies and related treatment records. Provide clear copies with translations when needed. The reviewing doctor may request additional information before giving an opinion.

Our care coordination team can review the initial information, help identify suitable doctors and hospitals, request a medical opinion where available, explain next steps and indicative cost information, and support practical planning before travel. A remote opinion does not replace an in-person examination or emergency care.